Clinical Trial Update: Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the oral investigational drug VX-765 for psoriasis has completed; the update does not include efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• VX-765 (belnacasan)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Psoriasis | Phase 2 | Status: COMPLETED